Zobrazeno 1 - 10
of 3 211
pro vyhledávání: '"Cdk2"'
Publikováno v:
Cancer Cell International, Vol 24, Iss 1, Pp 1-16 (2024)
Abstract Objective As colorectal cancer (CRC) remains one of the leading causes of cancer-related deaths, understanding novel therapeutic mechanisms is crucial. This research focuses on the role of extracellular vesicles (EVs) from bone marrow stroma
Externí odkaz:
https://doaj.org/article/cbb48a52b1b845728ec79f15f31c3758
Autor:
Heba T. Abdel-Mohsen
Publikováno v:
BMC Chemistry, Vol 18, Iss 1, Pp 1-19 (2024)
Abstract In the current study, molecular hybridization between the oxindole core and benzothiazole system through an acetohydrazide moiety was accomplished for the design of a new series of oxindole–benzothiazole hybrids 9a–r targeting CDK2 for c
Externí odkaz:
https://doaj.org/article/048975611d8546c29cb68c58a7531612
Autor:
Jianming Tang, Jing Li, Jiayan Lian, Yumei Huang, Yaqing Zhang, Yanwei Lu, Guansheng Zhong, Yaqi Wang, Zhitao Zhang, Xin Bai, Min Fang, Luming Wu, Haofei Shen, Jingyuan Wu, Yiqing Wang, Lei Zhang, Haibo Zhang
Publikováno v:
Journal of Advanced Research, Vol 61, Iss , Pp 239-251 (2024)
Introduction: Despite radiotherapy being one of the major treatments for triple-negative breast cancer (TNBC), new molecular targets for its treatment are still required due to radioresistance. CDK2 plays a critical role in TNBC. However, the mechani
Externí odkaz:
https://doaj.org/article/699eb4bf73654c89be43d53085bad4de
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionHeart failure (HF) and kidney failure (KF) are closely related conditions that often coexist, posing a complex clinical challenge. Understanding the shared mechanisms between these two conditions is crucial for developing effective therap
Externí odkaz:
https://doaj.org/article/7c2d9e82e7ea409d8aa0987494bcaf12
Publikováno v:
Frontiers in Chemistry, Vol 12 (2024)
Cyclin-dependent kinase 2 (CDK2) has been recognized as one of the crucial factors in cell cycle regulation and has been proposed as a potential target for cancer therapies, particularly for colorectal cancer (CRC). Due to the increased incidence rat
Externí odkaz:
https://doaj.org/article/7bdcc13fc7d84dad895a3d4ae5b5603c
Publikováno v:
Journal of Mazandaran University of Medical Sciences, Vol 33, Iss 230, Pp 28-39 (2024)
Background and purpose: To treat kidney cancer, methods such as surgery, chemotherapy, immunotherapy, etc. are used, which cause many side effects, thus, we try to use methods that have fewer side effects, such as the use of plant compounds. Consider
Externí odkaz:
https://doaj.org/article/c6ef0a3cfee24257ab74fc482f5c6a4c
Autor:
Eman M. Sayed, Etify A. Bakhite, Reda Hassanien, Nasser Farhan, Hanan F. Aly, Salma G. Morsy, Nivin A. Hassan
Publikováno v:
BMC Chemistry, Vol 18, Iss 1, Pp 1-19 (2024)
Abstract In this study, we synthesized new 5,6,7,8-tetrahydroisoquinolines and 6,7,8,9-tetrahydrothieno[2,3-c]isoquinolines based on 4-(N,N-dimethylamino)phenyl moiety as expected anticancer and/or antioxidant agents. The structure of all synthesized
Externí odkaz:
https://doaj.org/article/d2e4abd5a00840a0aa8071fdc5b84175
Publikováno v:
Xin yixue, Vol 55, Iss 1, Pp 5-11 (2024)
Objective To investigate the relationship between the expression of Zeste White 10 interactor（ZWINT）and Cyclin-dependent kinase 2（CDK2）and clinicopathological features in breast cancer，and evaluate their pathological diagnostic values in br
Externí odkaz:
https://doaj.org/article/53080470ea6243b187723daf029b8a9e
Publikováno v:
Journal of Bone Oncology, Vol 45, Iss , Pp 100594- (2024)
Background: Osteosarcoma, a tumor that originates from bone cells, has a poor prognosis and a high degree of malignancy. Anlotinib, a small-molecule multi-target tyrosine kinase inhibitor (TKI), is the first-line drug in treating osteosarcoma, especi
Externí odkaz:
https://doaj.org/article/654d781ccf2742afbaf74732a373aae9
Publikováno v:
BMC Complementary Medicine and Therapies, Vol 23, Iss 1, Pp 1-17 (2023)
Abstract Most of the breast cancers are estrogen receptor-positive recurring with a steady rate of up to 20 years dysregulating the normal cell cycle. Dinaciclib is still in clinical trials and considered as a research drug against such cancers targe
Externí odkaz:
https://doaj.org/article/f93741f067be4676b74fe9081dad3cfc